Open-label, Cross Over, Single-sequence, Two Periods Phase 1 Drug-drug Interaction Study to Evaluate the Effects of Multiple-dose Mefenamic Acid, a Known UGT1A9 Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Single-dose Sotagliflozin in Healthy Male and Female Subjects
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Sotagliflozin (Primary) ; Mefenamic acid
- Indications Diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Sanofi
- 06 Jun 2017 Status changed from not yet recruiting to completed.
- 07 Mar 2017 New trial record